Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T86704
|
||||
Target Name |
Phosphodiesterase (PDE) 3
|
||||
Target Type |
Successful
|
||||
Disease | Asthma [ICD10: J45] | ||||
Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10: J00, J30, J31.0, T78.4] | |||||
Allergy [ICD9: 995.3; ICD10: T78.4] | |||||
Arteriosclerosis [ICD9: 440; ICD10: I70] | |||||
Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10: J40-J44, J47] | |||||
Cardiovascular disorder [ICD10: I00-I99] | |||||
Cough [ICD9: 786.2; ICD10: R05] | |||||
Congestive heart failure [ICD9: 428; ICD10: I50] | |||||
Cardiotonic [ICD10: I50] | |||||
Heart failure [ICD9: 428; ICD10: I50] | |||||
Intermittent claudication [ICD9: 440.21; ICD10: I73.9] | |||||
Septic shock [ICD9: 785.52; ICD10: A41.9] | |||||
BioChemical Class |
Hydrolases (EC:3)
|
||||
EC Number |
EC 3.1.4.17
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Cilostazol | Drug Info | Approved | Intermittent claudication | [536186], [542155] |
Enoximone | Drug Info | Approved | Congestive heart failure | [536361] | |
Inamrinone Lactate | Drug Info | Approved | Cardiotonic | [551871] | |
Milrinone | Drug Info | Approved | Congestive heart failure | [468278], [536361] | |
Oxtriphylline | Drug Info | Approved | Cough | [538364] | |
K-134 | Drug Info | Phase 2 | Arteriosclerosis | [522473] | |
Org-30029 | Drug Info | Phase 2 | Heart failure | [534035] | |
RPL-554 | Drug Info | Phase 2 | Allergic rhinitis | [525173] | |
Tipelukast | Drug Info | Phase 2 | Asthma | [525273] | |
349U85.HCL | Drug Info | Phase 1 | Cardiovascular disorder | [526644], [533980] | |
SDZ-MKS-492 | Drug Info | Phase 1 | Asthma | [533607], [533957] | |
NSP-805 | Drug Info | Discontinued in Phase 2 | Heart failure | [545097] | |
OPC-8490 | Drug Info | Discontinued in Phase 2 | Cardiovascular disorder | [544607] | |
Org-9731 | Drug Info | Discontinued in Phase 2 | Heart failure | [545949] | |
Pumafentrine | Drug Info | Discontinued in Phase 2 | Asthma | [547102] | |
Tolafentrine | Drug Info | Discontinued in Phase 2 | Chronic obstructive pulmonary disease | [545580] | |
NIP-520 | Drug Info | Discontinued in Phase 1 | Asthma | [547049] | |
R 80122 | Drug Info | Discontinued in Phase 1 | Cardiovascular disorder | [544843] | |
Benafentrine dimaleate | Drug Info | Terminated | Septic shock | [544550] | |
Org-9935 | Drug Info | Terminated | Asthma | [546889] | |
SDZ-ISQ-844 | Drug Info | Terminated | Asthma | [545901] | |
Siguazodan | Drug Info | Terminated | Allergy | [544635] | |
UD-CG-212 | Drug Info | Terminated | Heart failure | [526768] | |
ZARDAVERINE | Drug Info | Terminated | Chronic obstructive pulmonary disease | [544526] | |
Modulator | 349U85.HCL | Drug Info | [533980] | ||
Benafentrine dimaleate | Drug Info | [533628] | |||
Cilostazol | Drug Info | [556264] | |||
Enoximone | Drug Info | ||||
Inamrinone Lactate | Drug Info | ||||
K-134 | Drug Info | [531714], [544269] | |||
Milrinone | Drug Info | [556264] | |||
NIP-520 | Drug Info | [1572591] | |||
NSP-805 | Drug Info | ||||
OPC-8490 | Drug Info | ||||
Org-30029 | Drug Info | [534035] | |||
Org-9731 | Drug Info | [533708] | |||
Org-9935 | Drug Info | ||||
Oxtriphylline | Drug Info | [556264] | |||
Pumafentrine | Drug Info | ||||
R 80122 | Drug Info | [535804] | |||
RPL-554 | Drug Info | ||||
SDZ-ISQ-844 | Drug Info | [533858] | |||
SDZ-MKS-492 | Drug Info | [533607], [533957] | |||
Siguazodan | Drug Info | ||||
Tipelukast | Drug Info | ||||
Tolafentrine | Drug Info | ||||
UD-CG-212 | Drug Info | ||||
ZARDAVERINE | Drug Info | ||||
References | |||||
Ref 468278 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5225). | ||||
Ref 522473 | ClinicalTrials.gov (NCT00783081) Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication. U.S. National Institutes of Health. | ||||
Ref 525173 | ClinicalTrials.gov (NCT02427165) Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients. U.S. National Institutes of Health. | ||||
Ref 525273 | ClinicalTrials.gov (NCT02503657) Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF). | ||||
Ref 526644 | Cardiovascular pharmacology of the vasodilator-cardiotonic agent, 349U85. J Cardiovasc Pharmacol. 1992 Oct;20(4):579-89. | ||||
Ref 526768 | Electrophysiological actions of the pimobendan metabolite, UD-CG 212 Cl, in guinea pig myocardium. J Pharmacol Exp Ther. 1992 Jan;260(1):58-63. | ||||
Ref 533607 | Effects of MKS-492 on antigen-induced bronchoconstriction and allergic reaction in guinea pigs and rats. Jpn J Pharmacol. 1993 Dec;63(4):405-13. | ||||
Ref 533957 | Effects of a cyclic nucleotide phosphodiesterase isoenzyme type III inhibitor, SDZ MKS 492 on airway responsiveness in beagles. Arerugi. 1993 Aug;42(8):920-5. | ||||
Ref 533980 | Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects. Clin Pharmacol Ther. 1994 Jan;55(1):55-63. | ||||
Ref 534035 | Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606. | ||||
Ref 536186 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 538364 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 086742. | ||||
Ref 542155 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7148). | ||||
Ref 544526 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000057) | ||||
Ref 544550 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000110) | ||||
Ref 544607 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000283) | ||||
Ref 544635 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000375) | ||||
Ref 544843 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001304) | ||||
Ref 545097 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002110) | ||||
Ref 545580 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003767) | ||||
Ref 545901 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005292) | ||||
Ref 545949 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005468) | ||||
Ref 546889 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010891) | ||||
Ref 547049 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012535) | ||||
Ref 531714 | A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg. 2012 Feb;55(2):381-389.e1. | ||||
Ref 533607 | Effects of MKS-492 on antigen-induced bronchoconstriction and allergic reaction in guinea pigs and rats. Jpn J Pharmacol. 1993 Dec;63(4):405-13. | ||||
Ref 533628 | Studies on anti-allergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways. Jpn J Pharmacol. 1995 Feb;67(2):149-56. | ||||
Ref 533708 | The effects of various drugs on the myocardial inotropic response. Gen Pharmacol. 1995 Jan;26(1):1-31. | ||||
Ref 533858 | Effects of inhaled SDZ ISQ 844, a cyclic nucleotide phosphodiesterase isoenzyme type III/IV inhibitor, on airway responsiveness in beagles. Arerugi. 1994 Apr;43(4):551-6. | ||||
Ref 533957 | Effects of a cyclic nucleotide phosphodiesterase isoenzyme type III inhibitor, SDZ MKS 492 on airway responsiveness in beagles. Arerugi. 1993 Aug;42(8):920-5. | ||||
Ref 533980 | Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects. Clin Pharmacol Ther. 1994 Jan;55(1):55-63. | ||||
Ref 534035 | Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606. | ||||
Ref 535804 | Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J Pharmacol Exp Ther. 1992 Oct;263(1):6-14. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.